S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Our #1 Laser Stock for May (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Our #1 Laser Stock for May (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Our #1 Laser Stock for May (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
Surprising "Twist" Hands Biden Landslide Re-election? (Ad)
Stock market today: Asian shares mostly rise, lifted by bull market on Wall Street
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Our #1 Laser Stock for May (Ad)
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
6 Best Online and Direct Marketing Retail Stocks to Invest in
The single greatest medical breakthrough of all time? (Ad)
Homebuilding Stocks Defying Cooling Housing Market: Time to Sell?
US applications for jobless benefits highest since October 2021
NASDAQ:BEAM

Beam Therapeutics (BEAM) Stock Forecast, Price & News

$33.45
-0.91 (-2.65%)
(As of 06/8/2023 ET)
Compare
Today's Range
$32.81
$34.66
50-Day Range
$29.32
$35.99
52-Week Range
$28.04
$73.27
Volume
491,356 shs
Average Volume
888,383 shs
Market Capitalization
$2.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.91

Beam Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
103.0% Upside
$67.91 Price Target
Short Interest
Bearish
21.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Beam Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$288,945 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.50) to ($6.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

816th out of 986 stocks

Biological Products, Except Diagnostic Industry

130th out of 160 stocks


BEAM stock logo

About Beam Therapeutics (NASDAQ:BEAM) Stock

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BEAM Stock News Headlines

Instantly Find Hidden Trade Opportunities
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
U.S. Loses to China in Shocking WAR GAMES
=== BREAKING === U.S. Loses to China in Shocking WAR GAMES Pentagon says new "living missile" key to winning a future conflict. Investors stand to reap 35,960% on shares of the small defense contractor that makes powerful new weapon. Get the name of the stock here >>>
Beam Therapeutics (NASDAQ:BEAM) PT Lowered to $42.00
8-K: Beam Therapeutics Inc.
See More Headlines

BEAM Price History

BEAM Company Calendar

Last Earnings
5/10/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BEAM
Fax
N/A
Employees
341
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$67.91
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+103.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$-289,090,000.00
Net Margins
-412.45%
Pretax Margin
-374.76%

Debt

Sales & Book Value

Annual Sales
$60.92 million
Book Value
$10.41 per share

Miscellaneous

Free Float
72,863,000
Market Cap
$2.55 billion
Optionable
Not Optionable
Beta
1.63

Social Links


Key Executives

  • Mr. John M. Evans M.B.A.Mr. John M. Evans M.B.A. (Age 45)
    CEO & Director
    Comp: $1.02M
  • Dr. Giuseppe Ciaramella Ph.D. (Age 54)
    Pres & Chief Scientific Officer
    Comp: $890.79k
  • Ms. Terry-Ann Burrell M.B.A.Ms. Terry-Ann Burrell M.B.A. (Age 46)
    CFO & Treasurer
    Comp: $687.52k
  • Dr. Feng Zhang Ph.D.
    Co-Founder
  • Dr. David R. Liu Ph.D.
    Co-Founder
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Nicole Gaudelli Ph.D.
    Co-Founder
  • Dr. Alexis Komor Ph.D.
    Co-Founder
  • Ms. Suzanne Fleming (Age 62)
    Chief Accounting Officer
  • Mr. Brian Riley (Age 46)
    Sr. VP of Technical Operations













BEAM Stock - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BEAM shares.
View BEAM analyst ratings
or view top-rated stocks.

What is Beam Therapeutics' stock price forecast for 2023?

10 Wall Street research analysts have issued 12-month target prices for Beam Therapeutics' shares. Their BEAM share price forecasts range from $37.00 to $105.00. On average, they predict the company's share price to reach $67.91 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price.
View analysts price targets for BEAM
or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2023?

Beam Therapeutics' stock was trading at $39.11 on January 1st, 2023. Since then, BEAM stock has decreased by 14.5% and is now trading at $33.45.
View the best growth stocks for 2023 here
.

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BEAM earnings forecast
.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) released its earnings results on Wednesday, May, 10th. The company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.03. The company had revenue of $24.21 million for the quarter, compared to analyst estimates of $14.41 million. Beam Therapeutics had a negative trailing twelve-month return on equity of 42.04% and a negative net margin of 412.45%.

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Beam Therapeutics' stock symbol?

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.84%), FMR LLC (8.15%), BlackRock Inc. (7.08%), Temasek Holdings Private Ltd (5.48%), Farallon Capital Management LLC (4.60%) and State Street Corp (4.25%). Insiders that own company stock include Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends
.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Beam Therapeutics' stock price today?

One share of BEAM stock can currently be purchased for approximately $33.45.

How much money does Beam Therapeutics make?

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $2.55 billion and generates $60.92 million in revenue each year. The company earns $-289,090,000.00 in net income (profit) each year or ($4.45) on an earnings per share basis.

How many employees does Beam Therapeutics have?

The company employs 341 workers across the globe.

Does Beam Therapeutics have any subsidiaries?
The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More
How can I contact Beam Therapeutics?

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com.

This page (NASDAQ:BEAM) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -